Wall Street brokerages forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report earnings of ($0.76) per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.71). Lexicon Pharmaceuticals posted earnings of ($0.16) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 375%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 11th.
On average, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.79 per share for the current year, with EPS estimates ranging from $0.71 to $0.87. For the next year, analysts expect that the business will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.40) to ($1.94). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The firm had revenue of $294.45 million during the quarter, compared to analysts’ expectations of $12.00 million. During the same quarter in the previous year, the business earned ($0.26) earnings per share. The company’s revenue was up 4124.5% on a year-over-year basis.
Several research firms have recently weighed in on LXRX. Wedbush restated a “buy” rating and issued a $17.00 price target on shares of Lexicon Pharmaceuticals in a research note on Sunday, December 22nd. BidaskClub cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 25th. Gabelli cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. They noted that the move was a valuation call. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and an average target price of $6.50.
Shares of LXRX stock traded down $0.20 during mid-day trading on Friday, hitting $4.04. The company’s stock had a trading volume of 911,492 shares, compared to its average volume of 1,158,204. Lexicon Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $8.39. The business has a 50-day moving average price of $4.26 and a 200 day moving average price of $3.56. The company has a debt-to-equity ratio of 1.42, a quick ratio of 8.01 and a current ratio of 8.11. The stock has a market cap of $450.59 million, a price-to-earnings ratio of 3.12 and a beta of 1.02.
Institutional investors have recently bought and sold shares of the stock. Pictet Asset Management Ltd. increased its position in Lexicon Pharmaceuticals by 9.6% during the third quarter. Pictet Asset Management Ltd. now owns 729,876 shares of the biopharmaceutical company’s stock valued at $2,197,000 after acquiring an additional 64,100 shares during the last quarter. Millennium Management LLC increased its position in Lexicon Pharmaceuticals by 4.5% during the third quarter. Millennium Management LLC now owns 1,220,629 shares of the biopharmaceutical company’s stock valued at $3,674,000 after acquiring an additional 53,092 shares during the last quarter. Vanguard Group Inc. increased its position in Lexicon Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after acquiring an additional 319,382 shares during the last quarter. Morgan Stanley increased its position in Lexicon Pharmaceuticals by 158.0% during the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 119,611 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Lexicon Pharmaceuticals during the third quarter valued at $202,000. Institutional investors own 96.24% of the company’s stock.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.